poland
Cables on Poland Reimbursements for pharmaceutical drugs
From KEI staff review of Wikileaks cables (http://keionline.org/wikileaks)
The US Department of States has been deeply involved in pushing the Poland government to provide more industry favorable rules for setting reimbursements for pharmaceutical drugs. Below are links to discussions of some of the cables published in 2011 by Wikileaks:
2009 January 14 cable on Poland pharmaceutical reimbursement list
This is one of several Wikileaks cables on Poland pharmaceutical reimbursements.
Some highlights from this cable:
- Pfizer's head of government affairs estimated it contains about 10 new molecules without generic competitors. Meaningful access to the Polish market often hinges on a drug appearing on the list, since those drugs are subsidized by the National Health Fund (NFZ) and doctors most often prescribe drugs from the list.
2008 May 14 Cable: Poland wants to cap drug cost effectiveness at 3x GDP/pop. Pfizer wants 6x
September 3, 2011
From KEI staff review of Wikileaks cables (http://keionline.org/wikileaks)
On May 14, 2008, The US Embassy in Warsaw sent a cable that discussed additions to the list of pharmaceutical products reimbursed by the government.
A few highlights from this cable:
2006 Cable: US, UK, French, German and Danish officials lobby against Polish price cuts for pharmaceutical drugs
September 3, 2011
From KEI staff review of Wikileaks cables (http://keionline.org/wikileaks)
This July 3, 2006 cable discusses a U.S. mobilization to oppose a reduction in pharmaceutical prices in Poland. The cable notes that
United States Trade Representative (USTR) FOIA requests
Submitted by James Love on 12. September 2009 - 10:34Before (or after) reading these accounts of FOIA requests to USTR, you might also review the transparency memorandum issued by President Obama in January 2009.
The following are some recent FOIA requests for USTR:
